Jhanelle E. Gray, Soner Altiok, Mark G. Alexandrow, Frank W. Walsh, Jian Chen, Michael J. Schell, Datchen Fritz Tai and Gerold Bepler Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers Cancer 119
Version of Record online: 12 OCT 2012 | DOI: 10.1002/cncr.27836
This chemoprevention trial is the first using a non-US Food and Drug Administration-approved, oral, small-molecule–targeted agent. Although the primary endpoint has not been met, the results indicate that enzastaurin is tolerable for 6 months by 75% of participants with a 19% positive response rate in all metaplastic or dysplastic lesions post-treatment.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field